Intranasal Etripamil shows potential for AF with fast ventricular rate control: AHA 2023
Despite chronic therapies, atrial fibrillation (AF) leads to fast ventricular rates (FVR) often requiring emergency department visits for intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally that has previously been shown to be of benefit in paroxysmal supraventricular tachycardia (PSVT) patients as an emergency self-administered measure. The recently presented phase 2 ReVeRA-201 study at AHA 2023 conference has shown that this drug provides quick relief for patients with AF accompanied by FVR. The results were simultaneously published in Circulation: Arrhythmia and Electrophysiology journal.
Etripamil is an L-type calcium channel blocker that has been formulated as a nasal spray for both rapid onset of action and a short-lasting plasma exposure. It has been studied as a self-administered therapy for patients with PSVT, demonstrating rapid termination of the arrhythmia, reduced visits to the emergency department, and possibly fewer medical interventions.
In the ReVeRA-201 trial, which took place at 23 locations in Canada and the Netherlands, researchers examined the impact of the nasal spray on patients who arrived at the emergency department with any form of atrial fibrillation (AF) and a rapid ventricular rate (≥ 110 bpm). Participants were randomly assigned to receive either etripamil or a placebo, and the nasal sprays were administered by medical personnel.
The primary objective was to demonstrate the effectiveness of etripamil in reducing VR in AF-FVR within 60 min of treatment. Secondary objectives assessed achievement of VR <100 bpm, reduction by ≥10 and ≥20%, relief-of-symptoms and treatment-effectiveness; adverse events (AEs); and additional measures to 360 min.
Authors found that:
1. The mean maximum reduction in ventricular rate over the first 60 minutes after the spray was administered, and this was, on average, 29.91 bpm greater in the etripamil arm.
2. Etripamil also resulted in greater proportions of patients who achieved a ventricular rate < 100 bpm, at least a 10% reduction in the rate, and at least a 20% reduction in the rate.
3. The median time needed to get below 100 bpm was just 7 minutes.
The researchers also assessed patient-reported outcomes through the Treatment Satisfaction Questionnaire for Medication-9. Participants treated with etripamil gave higher ratings for effectiveness and overall satisfaction when compared to those who received the placebo. On the individual question of symptom relief, patients treated with etripamil reported a higher rating.
Regarding safety, the predominant treatment-emergent adverse events were related to the drug administration site, with higher occurrences of nasal discomfort and rhinorrhea observed in the etripamil group. In the etripamil group, two instances of bradyarrhythmia were reported, while the placebo group had two cases of intracardiac thrombus.
The current study addresses an important gap in care for patients with atrial fibrillation and FVR. It may be a novel development to be able to self-administer a drug if one has AF with FVR and be able to avoid the emergency room visits.
Source: Camm AJ, Piccini JP, Alings M, et al. A multicenter, phase 2, randomized, controlled study of the efficacy and safety of etripamil nasal spray for the acute reduction of rapid ventricular rate in patients with symptomatic atrial fibrillation (ReVeRA-201). Circ Arrhythm Electrophysiol. 2023
